Bio Path Story

<div class='circular--portrait' style='background:#3b5998;color: #F0F8FF;font-size:4em;'>BP</div>
BPTH -- USA Stock  

USD 3.47  0.09  2.53%

The next fiscal quarter end is expected on the 30th of September 2020. The stock goes through an active upward rally. Because some millenniums are getting more into healthcare space, we are going to concentrate on the feasibility of inclusion Bio Path into your portfolio. What exactly are Bio Path shareholders getting in September?
Published over three months ago
View all stories for Bio Path | View All Stories
Will Bio Path Holdings price rise in September?
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Bio Path has an asset utilization ratio of 0.34 percent. This implies that the company is making $0.00344 for each dollar of assets. An increasing asset utilization means that Bio Path Holdings is more efficient with each dollar of assets it utilizes for everyday operations.
What is the right price you would pay to acquire a share of Bio Path? For most investors, it would be the price that gives them a wide margin of safety to have minimal downside risk. In other words, most investors are always looking for undervalued stocks. Even if the future performance is not entirely as expected, the loss of holding it is minimized, and the downside risk is negated. Please read more on our stock advisor page.

What is happening with Bio Path Holdings this year

Annual and quarterly reports issued by Bio Path Holdings are formal financial statements that are published yearly and quarterly and sent to Bio Path stockholders. The reports show and break down the current year's ongoing operations and discuss plans for the upcoming year. Annual reports have been a requirement from the Securities and Exchange Commission (SEC) for businesses owned by the public since 1934. Companies such as Bio Path often view their annual report as an effective marketing tool to disseminate their perspective on company future earnings or innovations. With this in mind, many companies devote large sums of money to making their reports attractive and informative. In such instances, the annual report becomes a forum through which a company can communicate to the general public any number of topics that may or may not be directly related to the actual data published in the reports.

How Bio Path utilizes its cash?

To perform a cash flow analysis of Bio Path, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash Bio Path is receiving and how much cash it distributes out in a given period. The Bio Path cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. Bio Path Net Cash Flow from Operations is most likely to decrease significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (8.36 Million)

Acquisition by Amy Sing of 25000 shares of Bio Path subject to Rule 16b-3

Legal trades by Bio Path insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:
Bio Path insider trading alert for grant of common stock option (right to buy) by Amy Sing, the corporate stakeholder, on 23rd of August 2020. This event was filed by Biopath Holdings Inc with SEC on 2016-04-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]   
Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

Is Bio Path a risky opportunity?

Let's check the volatility. Bio Path is looking slightly risky at this time. Whether you invest your money or manage your clients' funds, remember that it is easy to forget that behind Bio Path (NASDAQ:BPTH) stock is an actual business venture. So, do not let stock picking become an abstract concept by ignoring the elementary risk calculations. locking in a share of a Bio Path stock makes you a part-owner of that company.

Bio Path implied volatility may change after the rise

Current value at risk is at -6.67. Bio Path Holdings exhibits very low volatility with skewness of -0.41 and kurtosis of 6.38. However, we advise investors to further study Bio Path Holdings technical indicators to make sure all market info is available and is reliable.

Our Final Perspective on Bio Path

While some other firms under the biotechnology industry are still a bit expensive, Bio Path may offer a potential longer-term growth to stockholders. On the whole, as of the 21st of August 2020, we believe that at this point, Bio Path is slightly risky with low odds of distress within the next 2 years. From a slightly different point of view, the entity appears to be undervalued. Our current 30 days buy-or-sell advice on the company is Cautious Hold.

About Contributor

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Raphi Shpitalnik do not own shares of Bio Path Holdings. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com